Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Titel:
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Auteur:
Schmid, Peter Rugo, Hope S Adams, Sylvia Schneeweiss, Andreas Barrios, Carlos H Iwata, Hiroji Diéras, Véronique Henschel, Volkmar Molinero, Luciana Chui, Stephen Y Maiya, Vidya Husain, Amreen Winer, Eric P Loi, Sherene Emens, Leisha A